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Synthetic cannabinoids (SCs) were initially developed as pharmacological tools to
probe the endocannabinoid system and as novel pharmacotherapies, but are now
highly abused. This is a serious public health and social problem throughout the
world and it is highly challenging to identify which SC was consumed by the drug
abusers, a necessary step to tie adverse health effects to the new drug’s toxicity.
Two intrinsic properties complicate SC identification, their often rapid and extensive
metabolism, and their generally high potency relative to the natural psychoactive
1
9-tetrahydrocannabinol in cannabis. Additional challenges are the lack of reference
standards for the major urinary metabolites needed for forensic verification, and the
sometimes differing illicit and licit status and, in some cases, identical metabolites
produced by closely related SC pairs, i.e., JWH-018/AM-2201, THJ-018/THJ-2201,
and BB-22/MDMB-CHMICA/ADB-CHMICA. We review current SC prevalence, establish
the necessity for SC metabolism investigation and contrast the advantages and
disadvantages of multiple metabolic approaches. The human hepatocyte incubation
model for determining a new SC’s metabolism is highly recommended after comparison
to human liver microsomes incubation, in silico prediction, rat in vivo, zebrafish, and
fungus Cunninghamella elegansmodels. We evaluate SCmetabolic patterns, and devise
a practical strategy to select optimal urinary marker metabolites for SCs. New SCs are
incubated first with human hepatocytes and major metabolites are then identified by
high-resolution mass spectrometry. Although initially difficult to obtain, authentic human
urine samples following the specified SC exposure are hydrolyzed and analyzed by
high-resolution mass spectrometry to verify identified major metabolites. Since some
SCs produce the same major urinary metabolites, documentation of the specific SC
consumed may require identification of the SC parent itself in either blood or oral fluid.
An encouraging trend is the recent reduction in the number of new SC introduced per
year. With global collaboration and communication, we can improve education of the
public about the toxicity of new SC and our response to their introduction.
Keywords: novel psychoactive substances, NPS, synthetic cannabinoid, SC, metabolism, urinary metabolites,
hepatocyte incubation
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INTRODUCTION
The endogenous cannabinoid system includes neurotransmitters
or endogenous cannabinoids, receptors, cannabinoid receptor
1 (CB1, mainly expressed in brain) and CB2 (particularly
abundant in immune tissues), and synthetic and degradation
pathways (Pertwee, 2012; Le Boisselier et al., 2017). Cannabinoid
pharmacology continues to expand with the identification of
other signaling pathways including the TRP receptors and gated
ion channels. Cannabinoid receptor ligands are also found
in phytocannabinoids, particularly 19-tetrahydrocannabinol
(THC), the primary psychoactive constituent produced in the
cannabis plant (Gurney et al., 2014; Carlier et al., 2017a).
Cannabis is the most widely used illicit drug globally, with the
WorldHealth Organization estimating that in 2013, 181.8million
people aged 15–64 used cannabis for nonmedical purposes
(World Health Organization, 2016). The United Nations Office
on Drugs and Crime World Drug Report 2015 indicated that
SCs represented 39% of all new psychoactive substances (United
Nations, 2016). From 2014 to 2015, 177 SCs were reported to the
United Nations Office on Drugs and Crime, with reports from 58
countries and territories.
Initially, synthetic cannabinoids (SCs) were developed as
pharmacological probes to explore the endogenous cannabinoid
system with potential treatment for inflammatory diseases and
cancer pain (Pertwee, 2006; Castaneto et al., 2014), but such
endeavors failed to date, with no SC progressing to clinical use.
Typical SC structures are shown in Figure 1. Synthetic THC
is an approved pharmacotherapy for the reduction of nausea
and vomiting following chemotherapy and to stimulate hunger
in HIV AIDS wasting disease. In June 2018, the US Food
and Drug Administration approved the first cannabinoid plant
extract (Epidiolex R©) for the treatment of seizures associated with
two rare and severe forms of epilepsy, Dravet’s and Lennox-
Gastaut seizure syndromes (US Food Drug Administration,
2018). Epidiolex has a high CBD content and<0.3% THC.
Many SCs are potent CB1 and/or CB2 agonists and elicit
cannabimimetic effects similar to THC. SCs were first identified
as recreational drugs of abuse in 2008 in Europe and Japan
(Elsohly et al., 2014; Kemp et al., 2016). SC are usually synthesized
by clandestine laboratories mainly in Asia, sold over the internet
and labeled “not for human consumption” (Figure 1). Initially,
SC were sprayed on dried plant material, but currently, small
bottles of solubilized SC are shipped to help avoid custom
detection, and the end user smokes or vapes the product (Spice
Addiction Support Organization, 2019).
Due to the important role of the endogenous cannabinoid
system in human health and behavior, the acute and chronic
effects of SC exposure are the primary concerns among
the scientific community, as described in recent reviews of
their adverse neurological, psychiatric, cardiorespiratory, and
gastrointestinal effects (Castaneto et al., 2014; Panlilio et al.,
2015; Cooper, 2016; Logan et al., 2017). Most common clinical
toxicities were not life-threatening, such as tachycardia,
agitation, drowsiness, vomiting/nausea, hallucinations,
confusion, hypertension, chest pain, dizziness/vertigo (Tait
et al., 2016); however, more severe outcomes, including death
occur (Elliott et al., 2015; Waugh et al., 2016). A notorious
outbreak associated with SCs occurred in the State of Mississippi
in April and May 2015. This public health emergency claimed
17 lives and involved 1,243 emergency room visits (Mississippi
State Department of Health, 2015; Kemp et al., 2016). Ingestion
of the toxic SC, later identified as MAB-CHMINACA, resulted
in hospitalization of more than 10% of the patients into intensive
care units. The Australian National Household’s first survey
reported that among Australians over 14 years old, 1.2% used
SCs in the previous year, and 0.4% used other NPS (Australian
Institute of Health Welfare, 2014). A total of 858 SC were
scheduled in Japan as narcotics or designated substances as of
April 2015 (Uchiyama et al., 2015).
Confirmation of SC identity is important to tie the adverse
events to the specific toxic compound and because different
SC analogs may have different scheduling status. For instance,
some SCs (such as THJ-018 and THJ-2201) share similar
urinary marker metabolites; THJ-2201 was scheduled in the
United States while THJ-018 was not (Drug Enforcement
Administration, 2017). Rarely do drug-abusers know which
SC or SCs they consumed, and severe potential drug-drug
interactions with other abused illegal drugs or therapeutics can
occur (Chimalakonda et al., 2012).
WHY DO WE STUDY SC METABOLISM?
Constantly emerging SCs pose a significant challenge for forensic
laboratories performing drugs-of-abuse testing, as initially SCs
are not incorporated into existing targeted screening methods.
One of the greatest current challenges in forensic toxicology is
the large number of novel psychoactive substances available, and
the difficulty in identifying the best analytical targets to detect
their abuse. All previously investigated SCs were extensively
metabolized, with little to no unchanged parent drug found
in human urine (Scheidweiler et al., 2015; Cannaert et al.,
2016; Diao et al., 2016b; Carlier et al., 2017b). Urine is the
most common matrix for drug testing because of its non-
invasive collection, adequate sample, higher drug concentrations
and longer detection window than either blood or oral fluid
(Hutter et al., 2018). Generally, phase I metabolites are the
best SC marker metabolites to document intake because they
have higher mass spectrometry responses and are more stable
than phase II metabolites over time. Forensic urine samples
are usually hydrolyzed by β-glucuronidase prior to mass
spectrometry analysis, increasing sensitivity by measuring free
and glucuronidatedmoieties. Of note, some hydroxylated urinary
metabolites are even more toxic than the parent SC themselves;
JWH-018 major metabolites, 4′-OH-JWH-018 and 5′-OH-JWH-
018, and AM-2201 metabolite, 4′-OH-AM-2201, remained full
agonists in nanomolar concentrations (Chimalakonda et al.,
2012). Therefore, metabolism studies on novel emerging
SC are essential.
The best approaches for investigating SC metabolism are in
humans. Unfortunately, controlled SC administration studies are
severely restricted due to ethical limitations. The first tenet for
controlled human administration studies is do no harm, and the
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FIGURE 1 | Structural scheme of synthetic cannabinoids (SCs) with different principal cores (blue), linkers (red), and secondary moieties (black). A few examples are
provided for each moiety’s diverse substructures.
lack of acute and chronic drug toxicity data limit our ability to
conduct such studies. It also makes no sense to routinely perform
such clinical trials for each new emerging SC. Other approaches
are available to identify and confirm human urinary SC
marker metabolites.
MODELS TO STUDY SC METABOLISM
The biotransformation of xenobiotics converts drugs into more
water soluble metabolites to achieve better elimination from the
human body (Costa et al., 2014). Although drug metabolism
occurs in the lungs, kidneys, intestine, heart and blood, the most
important organ for drug metabolism process is the liver, with its
many hepatic enzymes, especially those of the cytochrome P450
(CYP) family (Brandon et al., 2003; Xie et al., 2013; Diao et al.,
2015; Zhu et al., 2016).
In vitro models provide useful tools to assess human drug
metabolism according to their ability to reproduce human
biotransformations. In this review, the most common and well-
established in vitro metabolism models, human hepatocytes and
human liver microsomes (HLM), are compared in light of their
advantages and disadvantages; other approaches such as in silico
software prediction, rat in vivo, zebrafish incubation, and fungus
Cunninghamella elegans (C. elegans) models were also reviewed.
Human Hepatocyte Incubation
Human hepatocyte incubation is an excellent in vitro system
for drug biotransformation research due to its ability to reflect
metabolism in the intact human liver. Human hepatocytes are
isolated living cells containing the complete repertoire of phase
I and phase II drug metabolizing enzymes, necessary cofactors,
uptake and eﬄux drug transporters, and drug binding proteins
(Diao and Huestis, 2017).
At the National Institutes of Health/National Institute on
Drug Abuse, we established a strong collaboration with the
United States Drug Enforcement Administration (DEA) to
identify optimal marker metabolites of new SC. When DEA
seizures of a particularly toxic new SC they would purify and
provide us with the SC. We first determined the SC’s half-
life by quantifying the disappearance of the parent compound
during incubation with HLM, in order to best design the SC
human hepatocyte incubation experiment. By far, the most
challenging aspect was the high-resolution mass spectrometry
(HR-MS) analysis to identify the full spectrum ofmetabolites, and
those metabolites that best differentiated the SC from its closest
analogs. We also attempted to obtain authentic human urine
samples following specific SC ingestion through international
collaborations, enabling comparison of in vitro and in vivo
metabolites and clarifying the targets for SCs drug testing.
This workflow was successful in predicting major urinary
metabolites of many SCs, including AB-PINACA/5F-AB-
PINACA (Wohlfarth et al., 2015), AB-FUBINACA (Castaneto
et al., 2015), FDU-PB-22/FUB-PB-22 (Diao et al., 2016a), and
NM-2201 (Diao et al., 2017b) etc. For AB-FUBINACA, the
prominent metabolite following human hepatocyte incubation
was amide hydrolysis product M11 (Figure 2A). Consistently,
M11 was also the most abundant metabolite in human urine
after β-glucuronidase hydrolysis. Besides M11, M6 (aliphatic
hydroxylation) and M7 (amide hydrolysis product of M6) were
the primary metabolites after β-glucuronidase hydrolysis in both
human hepatocyte incubation and in human urine following AB-
FUBINACA intake. For, AB-PINACA, metabolites A23 and A16
were the major metabolites in human hepatocyte incubation and
in human urine after β-glucuronidase hydrolysis (Figure 2B).
Advantages
With modern cryopreservation techniques, high quality isolated
human hepatocytes are commercially available, and retain the
activity of most phase I and II enzymes (Silva et al., 1999). High
quality metabolic data are produced by this well-established and
well-characterized in vitromodel.
Disadvantages
Cryopreserved human hepatocytes are much more expensive
than HLM, and once a vial is thawed, it should be fully utilized
and never refrozen. Storage under liquid nitrogen is required and
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FIGURE 2 | Major metabolites of AB-FUBINACA (A) and AB-PINACA (B) following human hepatocytes incubation and in human urine samples after suspected
AB-FUBINACA and AB-PINACA intake. All metabolite nomenclatures are from the original manuscripts.
the viability of the hepatocytes must be checked after thawing.
Human hepatocytes account for about 80% of total liver volume;
however, other cells, i.e., Kupffer cells, may supply additional
required cofactors.
HLM Incubation
HLM incubation is currently the most popular in vitro
metabolism model, providing an affordable method to identify
target metabolites following CYP and UGT metabolism. The
popularity of this in vitro model is attributed to its simplicity
and widespread availability, and the ability to determine
specific metabolizing isozyme(s) by studying their activity in
the presence of specific inhibitors (Bickett et al., 1993). HLM
are hepatocyte endoplasmic reticulum vesicles prepared by
differential centrifugation. HLM contain primarily CYP, UGT
and esterase enzymes, accounting for about 95% of clearance
mechanisms for the top 200 drugs prescribed in the United States
in 2002 (Williams et al., 2004).
However, major metabolite discrepancies may occur between
those noted in HLM incubations and those found in human
urine following SC intake, i.e., in the metabolism of 5F-AKB-
48 and AM-2201 (Figure 3A; Diao and Huestis, 2017). The
probable reason is that the enzyme responsible for oxidative
defluorination, the primary metabolic pathway for a fluoropentyl
chain SC, is not located in HLM. In the case of AM-2201,
the HLM metabolic profile did not match satisfactorily with
metabolites identified in authentic urine specimens. AM-2201
HLM incubation produced N-desfluoropentyl, mono-hydroxyl,
di-hydroxyl, and the most abundant dihydrodiol metabolite
(Figure 3A; Sobolevsky et al., 2012). One researcher self-
administered 5mgAM-2201 to identify themajor human urinary
metabolites (Hutter et al., 2013). Four major metabolites were
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identified in the post administration urine samples, JWH-
018 N-(5-OH-pentyl), JWH-018 N-pentanoic acid, AM-2201
6-OH-indole, and AM-2201 N-(4-OH-pentyl). The highest
concentrations were for JWH-018 N-pentanoic acid and
JWH-018 N-(5-OH-pentyl); however, AM-2201 shared major
metabolites with JWH-018, i.e., JWH-018 N-(5-OH-pentyl)
and JWH-018 N-pentanoic acid. Thus, it is challenging to
differentiate AM-2201 from JWH-018 intake based on the
detection of these two metabolites in urine specimens. To
distinguish AM-2201 intake from JWH-018, detection of AM-
2201 6-OH-indole and AM-2201 N-(4-OH-pentyl) is essential.
Recently, Mogler et al. also reported discrepancies in the
metabolism of SC CUMYL-PEGACLONE between HLM and
human urine samples (Mogler et al., 2018). Following HLM
incubation, M15, a mono-hydroxylation metabolite on the
pentyl chain, was found in the highest concentration, and
no parent, CUMYL-PEGACLONE was detected in any of the
human urine samples (n = 30). Twenty-two different phase
I CUMYL-PEGACLONE metabolites were detected in human
urine. Metabolic pathways included mono-hydroxylation, di-
hydroxylation, dehydrogenation, N-dealkylation, β-oxidation
(pentyl side chain to a propionic acid metabolite), carbonyl
formation at the pentyl side chain, and combinations of
these biotransformations. The most abundant two metabolites
were identified as M20 and M09 (Figure 3B); M20 was a
metabolite with mono-hydroxylation on the γ-carbolinone core
and M09 was a further pentyl chain carbonylated metabolite
from M20. The authors proposed M20 and M09 as sensitive
and specific urinary markers to prove intake of CUMYL-
PEGACLONE. The metabolism of CUMYL-PEGACLONE was
unexpectedly different from previous cumyl-derivatives (Kevin
et al., 2017; Özt"urk et al., 2018; Staeheli et al., 2018),
which were mainly hydroxylated on the pentyl side chain,
whereas CUMYL-PEGACLONE was mainly hydroxylated on the
γ-carbolinone core.
Advantages
The major advantages of the HLM in vitro model are its
simplicity, low cost and well established record in drug
biotransformation research. These advantages facilitated recent
investigation on the structure-metabolism relationships of valine
and tert-leucine-derived SCs (Franz et al., 2019). Also, the specific
enzyme producing a metabolite can be identified with a simple
HLM system and specific inhibitors.
Disadvantages
The primary disadvantage is that HLM results cannot
quantitatively estimate in vivo human biotransformation,
because CYPs and UGTs are enriched in HLM and there is
a lack of competition with other enzymes. Also, drugs are
exposed directly to the metabolizing enzymes in HLM, without
the requirement to penetrate through cell membranes, as for
metabolism in authentic hepatocytes. This results in higher
biotransformation rates in HLM compared to the human
in vivo situation, but also compared to primary hepatocytes
(Sidelmann et al., 1996). Additionally, the absence of other
enzymes (e.g., Aldehyde oxidase [AOX], N-acetyltransferase
[NAT], Glutathione S-transferases [GST], and Sulfotransferase
[SULT]) and cytosolic cofactors may fail to produce metabolites
formed in intact hepatocytes (Diao et al., 2014). Unlike with
human hepatocyte incubations, scientists must determine
which co-factors to supplement in HLM incubations. This
requires extensive drug metabolism knowledge, especially
when the metabolic pathway and enzymes involved are
unknown. In addition, co-factors are expensive, although
commercially available.
The use of HLM incubations rather than hepatocyte
incubations in preclinical toxicology studies was the cause behind
the termination of c-Met inhibitor SGX-523 development. The
primary SGX-523 metabolic pathway in humans is oxidation by
aldehyde oxidase (AOX), yielding 2-quinolinone-SGX523. The
much lower solubility of 2-quinolinone-SGX-523 in urine vs.
SGX-523 is considered the major reason for renal toxicity. AOX
is located in the liver cytosol rather than in liver microsomes.
AOX expression is species specific, with presence in humans
and monkeys, and little in mouse, rat and dog. During the
early drug discovery phase, species comparison studies were
performed in liver microsomes, with the results misleading the
team to use rat and dog as the toxicology model animals. Since
there was little AOX enzyme expression in rat and dog, no toxic
metabolites were produced and the potential for human toxicity
was overlooked.
In silico Prediction
In pharmaceutical industry, early prediction of possible toxic
metabolites is important to preclinical and clinical decision-
making (Afzelius et al., 2007; T’Jollyn et al., 2011). Identification
of possible toxic metabolites in the drug discovery stage
enables earlier decisions on elimination of drug candidates
from further development. Adams et al utilized metabolism
prediction software to suggest that the urinary AMB-FUBINACA
de-esterified acid metabolite could identify AMB-FUBINACA
intake in a mass intoxication outbreak (Adams et al., 2017).
In 2011, T’jollyn et al. evaluated Meteor (Lhasa Ltd., Leeds,
UK), MetaSite (Molecular Discovery Ltd., Middlesex, UK),
and StarDrop (Optibrium Ltd., Cambridge, UK) software drug
metabolism tools (T’Jollyn et al., 2011). Meteor is a rule-based
(empirical) software tool (Langowski and Long, 2002). MetaSite
is an automated docking model with a reactivity correction
considering the reactivity components of an atom related to heme
that is designed to predict phase I CYP450 metabolism (Cruciani
et al., 2005). StarDrop uses a quantum mechanical approach for
the prediction of the relative involvement of CYP3A4, 2D6, and
2C9 of the query compound (Earnshaw, 2010). Its mechanism is
based on calculation of the energy barrier to electron removal,
considered to be the rate-limiting step in product formation.
The authors evaluating the state-of-the-art metabolite prediction
software concluded that it has many advantageous features
but needs refinement to obtain acceptable prediction profiles.
Synergistic use of different software packages could prove useful.
However, it is not practical for forensic laboratories to purchase
expensive in silico software licenses.
In our previous investigation of SC THJ-2201 metabolism,
we first utilized the MetaSite in silico prediction software
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FIGURE 3 | Major metabolites of AM-2201 (A) and CUMYL-PEGACLONE (B) following human liver microsomes (HLM) incubation and in human urine samples after
suspected AM-2201 and CUMYL-PEGACLONE intake.
prior to hepatocyte incubation and HR-MS analysis. The
software predicted 8 first-generation and 7 second-generation
metabolites (Diao et al., 2016c). The top predicted metabolites
were N-depentyl-THJ-018, 1′-OH-THJ-2201, 1′-carbonyl-THJ-
2201, and pent-1′-enyl-THJ-2201 (Figure 4). However, these
top predicted metabolites were inconsistent with the scenario
in human hepatocyte incubation and human urine. After
incubating THJ-2201 with human hepatocytes, 27 metabolites
were generated, with THJ-018 pentanoic acid (F25) and 5′-
OH-THJ-018 (F26) as the most abundant metabolites. F26 was
produced by oxidative defluorination of THJ-2201, with further
oxidation to F25. In a SC screening method, THJ-018 N-
pentanoic acid was the target marker metabolite for THJ-2201
intake (Gundersen et al., 2019).
MetaSite primarily focuses on CYP450 mediated metabolism
and does not simulate reactions mediated by non-CYP450
oxidases, such as aldehyde oxidase. The performance of MetaSite
for THJ-2201 metabolism most likely missed the oxidative
defluorination reaction because it was not catalyzed by CYP450.
Advantages
The major advantages of in silico software prediction are its
simplicity and rapidity. In silico prediction assists metabolite
identification without requiring a reference standard, incubation
or HR-MS.
Disadvantages
Some metabolism software does not include all drug
metabolizing enzymes in the simulation model, thus missing
some metabolite pathways. The in silico prediction model may
be effective for some drugs and SCs, but are not accurate for all.
Rat in vivo Model
Clinical studies on SC effects are hampered by the lack of
preclinical toxicology data. It also is impractical to conduct
clinical trials on each new SC due to the constant introduction
of novel SC into the illegal drug market. Thus, many researchers
study SC pharmacodynamics and pharmacokinetics in vivo
animal models. AM-2201 metabolism in rats has similarities
and differences from that in humans (Jang et al., 2014).
Predominant AM-2001 metabolites after hydrolysis of rat urine
with β-glucuronidase were JWH-018 N-pentanoic acid and AM-
2201 6-OH-indole (Figure 5A). Two additional metabolites,
JWH-018 N-(5-OH-pentyl) and AM-2201 N-(4-OH-pentyl),
were detected in lower abundance in rat urine. These four
metabolites also were the top four metabolites in human urine
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FIGURE 4 | In silico predicted THJ-2201 metabolites vs. its major metabolites observed after hepatocytes incubation and in human urine after THJ-2201 intake.
after self-administration of 5mg AM-2201 (Hutter et al., 2013).
However, the relative abundance of these 4 metabolites in human
urine was quite different from that in rat urine. In human
urine, JWH-018 N-pentanoic acid and JWH-018 N-(5-OH-
pentyl) were the most abundant metabolites (Figure 5A), while
AM-2201 N-(4-OH-pentyl) and AM-2201 6-OH-indole were
observed in lower concentrations.
Recently, Kevin et al. investigated MN-18 metabolism (Kevin
et al., 2018) in rat after intraperitoneal administration of 3
mg/mL MN-18. Only two metabolites were identified in rat
urine, the hydroxylated metabolite M3 and its glucuronide M10
(Figure 5B). However, following human hepatocyte incubation
with MN-18, 13 metabolites were observed (Figure 5B), with
the top 3 metabolites 1-pentyl-1H-indazole-3-carboxylic acid
(M5), naphthalene hydroxylated MN-18 (M7), and pentyl-
carbonylated MN-18 (M12) (Diao et al., 2017a). To reduce
confusion, metabolite names were directly taken from the
original literature; if the same nomenclature occurred in both
literatures, the font of the metabolites from the latter one is
in italicized.
Advantages
It is much easier and inexpensive to perform an in vivo rat
or mouse metabolism study than a controlled human drug
administration study. The collection of animal plasma and urine
samples is relatively easy. The rat model also has the advantage
of producing metabolite reference standards. If a major human
metabolite is present in rat urine, sufficient urine may be
collected to isolate and characterize metabolites and produce
reference SCmetabolite standards. Another significant advantage
of employing a rodent model is that it is possible to observe and
measure animal behavior and physiology while conducting the
SC metabolism study. In addition, the rodent model may detect
acute SC toxicity.
Disadvantages
Species differences in metabolism exist, as noted for the AOX
enzyme in the metabolism of SGX-523. AOX activity was high
in humans and monkeys, but almost absent in rat and dog. Some
researchers tried to study SC metabolism in the chimeric mouse
with humanized liver (De Brabanter et al., 2013). However,
the effectiveness of this model remains unclear because it was
not compared to major metabolites in human urine samples.
Even if the humanized mouse model is effective, the data
quality produced does not justify the high cost; additionally,
its limited commercial availability prevents its usage in routine
metabolism research.
Zebrafish Model
The zebrafish (Danio rerio) was initially introduced by Streisiger
as an animal model in genetic studies in the early 1980s;
the zebrafish is a small teleost (3–4 cm) typically from sweet
waters (Streisinger et al., 1981). Some important advantages are
associated with zebrafish for research, such as small size, easy
maintenance, low cost of breeding, and high reproductive rate.
Zebrafish is emerging as a predictive vertebrate animal model
for in vivo assessment of drug efficacy, toxicity, and safety.
Interestingly, some studies evaluated the ability of zebrafish
larvae at different stages of ripening to generate xenobiotic
metabolites (Alderton et al., 2010; Chng et al., 2012).
The similarities between adult zebrafish and human
metabolism were evaluated on the generation of phase
I metabolites of the sports doping agent—sibutramine
(de Souza Anselmo et al., 2017). Adult zebrafish produce
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FIGURE 5 | Major AM-2201 metabolites (A) in rat urine vs. human urine and (B) MN-18 metabolites in rat urine vs. those after human hepatocytes incubation.
several sibutramine metabolites (Figure 6A), including
demethylsibutramine (nor-sib), bi-demethylsibutramine (bis-
nor-sib), hydroxylated nor-sib (OH-nor-sib1 and OH-nor-sib2),
and hydroxylated bis-nor-sib (OH-bis-nor-sib1 and OH-bis-
nor-sib2). These metabolites were identified in zebrafish culture
solution samples after hydrolysis with β-glucuronidase. The
authors claimed that the study demonstrated that adult zebrafish
could absorb, oxidize, and excrete several metabolites in a
manner similar to humans. However, although these metabolites
were observed in human urine, the major metabolites were
quite different. In zebrafish incubation samples, the top two
metabolites were demethylsibutramine (nor-sib) and bi-
demethylsibutramine (bis-nor-sib), but, these two metabolites
were only minor metabolites in human urine (Figure 6B). Eight
phase II carbamoyl glucuronides of nor-sib and bis-nor-sib
were the main metabolites in human urine (Link et al., 2006).
Of note, the author did not hydrolyze the human urine sample
with β-glucuronidase solution, so we cannot conclude whether
nor-sib/bis-nor-sib or OH-nor-sib/OH-bis-nor-sib were the
major human urine marker metabolites.
Advantages
Metabolism studies are convenient and feasible for laboratories
with an available zebrafish culture platform. In such a setting,
zebrafish culture is routine and cost-efficient, and it is easy to
maintain and to train new staff. The zebrafish can produce many
human-like phase I oxidative and reductive metabolites, and it
may be possible to generate a large metabolite mass to allow
isolation and structure elucidation.
Disadvantages
Typical forensic and clinical laboratories do not have experience
with the zebrafish culture platform, and drug metabolism
investigations take several days before harvesting the excretion
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FIGURE 6 | Metabolic pathway of sibutramine after Zebrafish incubation (A) and in human urine (B). Bold arrows denote major metabolic pathways and narrow
arrows for minor pathways.
sample in the culture tank. Species differences between zebrafish
and human metabolism may limit expansion of the zebrafish
cultural model.
Fungus C. elegans Incubation
The use of microorganisms, and particularly fungus C. elegans
as models to study human metabolism is well established and
provides another approach to producing SC metabolites (Asha
and Vidyavathi, 2009; Murphy, 2015). A review on C. elegans
metabolism reported that the fungus has some similarities with
human metabolism for various drugs (Asha and Vidyavathi,
2009). This cost-efficient system is capable of producing large
quantities of metabolites. In addition, the fungus culture is easy
to grow and can be transferred to new agar plates with ease
(Choudhary et al., 2007).
Watanabe et al. made significant contributions on
investigating the metabolism of SCs with the C. elegans model,
and evaluated the similarity of metabolites generated in this
incubation system with those observed in human metabolism
(Watanabe et al., 2016, 2017, 2018a,b). SC metabolites for
JWH-018, AM2201, JWH-073, PB-22, 5F-PB-22, XLR-11, and
UR-144 were evaluated in the C. elegans incubation model.
Some of the major phase I human metabolites of previously
investigated SCs were documented, although this model was less
effective in producing phase II human metabolites. The authors
proposed that the fungus C. elegans is a complementary model to
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study human metabolism of novel SC and can generate sufficient
SC metabolites for definitive structure elucidation.
When comparing C. elegans SC metabolites to human SC
metabolites, there are similarities for some SCs but there were
inconsistencies as well. For JWH-018 (Figure 7A), JWH-018
N-(4-OH-pentyl) and JWH-018 N-pentanoic acid were the top
two metabolites in human urine collected from individuals
with SC intoxication (Diao and Huestis, 2017). In the C.
elegans incubation system, JWH-018 N-(4-OH-pentyl) was also
the most abundant metabolite, matching quite well with the
human metabolites (Watanabe et al., 2016). But the other
abundant human metabolite, JWH-018 N-pentanoic acid, was
a minor metabolite in C. elegans incubation model. For AM-
2201 (Figure 7B), the primary human urinary metabolites were
JWH-018 N-(5-OH-pentyl), JWH-018 N-pentanoic acid, AM-
2201 6-OH-indole, AM-2201 N-(4-OH-pentyl). Although these
metabolites were detected in the C. elegans incubation model,
they had low abundance (Watanabe et al., 2016). In the C. elegans
incubation model, the top two metabolites were Mc25 (AM-2201
dihydrodiol) and Mc47 (JWH-073). This is most likely attributed
to the lack or low activity of the enzyme responsible for oxidative
defluorination, which phenomenon was also observed in HLM
incubation system.
Advantages
The C. elegans incubation system for metabolism of drugs offers a
convenient, low cost approach for laboratories with access to this
fungus culture platform. C. elegans culture is easy to maintain
and train new staff. C. elegans incubation can generate many
human phase I metabolites via different metabolic pathways,
such as hydroxylation, dihydrodiol formation, carboxylation,
dehydrogenation, and ketone formation etc. In addition, it is a
useful model for large scale metabolite preparation compared
to HLM or human hepatocytes incubation. In some cases,
metabolite reference standards are difficult to synthesize and for
example, the exact position of hydroxyl groups on the indole
FIGURE 7 | Metabolic pathway of JWH-018 (A) and AM-2201 (B) after fungus Cunninghamella elegans incubation vs. human urine.
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or indazole may not be elucidated by high-resolution mass
spectrometry alone. Therefore, C. elegans incubation is a good
model to produce and isolate metabolites.
Disadvantages
Most forensic and clinical laboratories do not have a fungus
C. elegans culture platform and related experience. Drug
metabolism investigations in C. elegans culture may take several
days before harvesting the incubation sample. Although C.
elegans have some CYP450 enzymes similar to those found
in humans, inconsistencies in metabolism occur, limiting the
expansion of the fungus C. elegans model to predict human
SC metabolism.
SC METABOLIC PATTERNS
A typical SC structure contains a principal core (with various side
chains), a linker, and a secondary moiety (Figure 1). The linker
FIGURE 8 | Metabolic patterns of SCs with different principal cores, linkers, and secondary moieties. Major metabolic sites were highlighted in red. (A) Carbonyl linker
(pentyl), (B) Carbonyl linker (fluoropentyl), (C) Ester linker (pentyl), (D) Ester linker (fluoropentyl), (E) Amide linker (pentyl), (F) Amide linker (fluoropentyl), (G) Amide linker
(fluorobenzyl).
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refers to the bridge between the principal core, i.e., pentylindole,
and the secondary moiety, i.e., naphthalene. The linker can be
carbonyl, ester or amide among different SCs (Andersson et al.,
2016; Carlier et al., 2018).
Fluorine-for-hydrogen replacement at the terminal carbon
of pentyl in pentylindole/pentylindazole SC is a typical SC
structural design, which generally enhanced potency (Gurney
et al., 2014). Such analogs include JWH-018/AM2201, PB-22/5F-
PB-22, UR-144/XLR-11, AKB-48/5F-AKB-48, THJ-018/THJ-
2201, AB-PINACA/5F-ABPINACA, and MN-18/5F-MN-18 etc.
Wohlfarth et al proposed that these SC pairs shared similar
major metabolic pathway patterns (Wohlfarth et al., 2015).
In general, SCs with pentyl side chains were preferentially
metabolized on the pentyl chain, especially the penultimate and
terminal carbons. SCs with a 5-fluoropentyl side chain were
predominantly metabolized on the terminal carbon, yielding
5-OH-pentyl and subsequent pentanoic acids. However, novel
SCs emerging onto the abused-drug market have more diverse
structures and this metabolic pathway may not occur. Later SC
generationsmetabolism alsomay be different when an alternative
to the early carbonyl linkage is present.
Based on our SC metabolism experience and other published
literature, we summarize SC metabolism patterns as follows.
(1) Carbonyl linker (pentyl). This group includes SCs that
contains a carbonyl linker, a principal core of a pentylindole
or pentylindazole, and a secondary moiety of naphthalene
or quinine (Figure 8A). The primary metabolic pathway
for these SCs is hydroxylation at ω- (terminal) and ω-1-
(penultimate) carbons of the pentyl side chain. Subsequent
oxidation of ω-hydroxyl-pentyl and ω-1-hydroxyl-pentyl
produces pentanoic acid and ω-1-carbonylated metabolites
(Figure 8A). Besides pentyl chain containing SCs, these
biotransformations also apply to pharmaceuticals that
contains aliphatic side chains, such as sameridine and
3-n-butylphthalide (Sohlenius-Sternbeck et al., 2000;
Diao et al., 2013a,b).
(2) Carbonyl linker (fluoropentyl). This group includes SCs
that have a carbonyl linker, a principal core of ω-fluoro-
pentylindole or ω-fluoro-pentylindazole, and a secondary
moiety of naphthalene or quinine (Figure 8B). Their
predominant biotransformation is oxidative defluorination
to ω-hydroxyl-pentyl SC and further oxidation to
pentanoic acid; these two major metabolites were the
same as those from corresponding SCs containing a
pentyl side chain. Other major metabolites, mainly
ω-1- and indole/indazole hydroxylated metabolites with
retention of fluorine, are additional characteristic marker
metabolites (Figure 8B).
(3) Ester linker (pentyl). This group includes SCs that contain
an ester linker, a principal core of pentylindole or
pentylindazole, and a secondary moiety of naphthalene
or quinine (Figure 8C). The most important metabolic
pathway for these SCs was ester hydrolysis, rather than
modification on the pentyl or fluoropentyl chain. The
generated carboxylic acid was the single most abundant
marker metabolite (Figure 8C). Although this carboxylic
acid metabolite with a pentyl chain undergoes further
ω-1-hydroxylation, the extent of this oxidation was much
less compared with SCs with a carbonyl linker (Figure 8A).
(4) Ester linker (fluoropentyl). These SCs contain an ester
linker, a principal core of ω-fluoro-pentylindole or
ω-fluoro-pentylindazole, and a secondary moiety of
naphthalene or quinine (Figure 8D). Primary metabolism
for these SCs also was ester hydrolysis, with little
oxidative defluorination of the ω-fluoro-pentyl chain
(Wohlfarth et al., 2014; Diao et al., 2017b).
(5) Amide linker (pentyl). SCs that contain an amide linker,
a principal core of a pentylindole or pentylindazole, and a
secondary moiety of aminooxobutane comprise this group
(Figure 8E). The primary metabolic pathway for these SCs
is hydrolysis of the terminal amide to a carboxylic acid and
further carbonylation, most likely on ω-1- carbon of the
pentyl chain.
(6) Amide linker (fluoropentyl). These SCs have an amide
linker, a principal core of ω-fluoro-pentylindole or ω-
fluoro-pentylindazole, and a secondary aminooxobutane
moiety (Figure 8F). The major metabolic pathways for these
SCs include not only hydrolysis of the terminal amide to
carboxylic acid, but also oxidative defluorination of the ω-
hydroxyl-pentyl SC and further oxidation to pentanoic acid.
(7) Amide linker (fluorobenzyl). These SCs have an amide
linker, a principal core of 4-fluoro-benzyl, and a secondary
moiety of an aminooxobutane (Figure 8G). Hydrolysis of the
terminal amide to a carboxylic acid is the most important
metabolic pathway. Hydroxylation on the aminooxobutane
occurred before and after hydrolysis.
IDENTIFICATION OF SPECIFIC SC INTAKE
Since human SC metabolism studies are rare and generally
occur far after introduction of a new SC, one way to identify
optimal urinary marker metabolites is performing metabolite
profiling of authentic urine specimens (overdose emergency
cases, driving under the influence of drugs cases, or when
an individual found in possession of SCs). Paired blood
and urine samples are difficult to obtain; they are highly
valuable if available. In general, novel SCs are extensively
metabolized primarily by human liver enzymes. Metabolites
are mainly excreted in human urine, with parent SCs rarely
detected in urine. Parent SC are detected in human blood
and/or oral fluid if the sample is collected as close as
possible to the time of intake. In addition, metabolites may
be present in blood depending upon the dose and time after
ingestion. However, caution is advised. Urinary metabolites may
be present that derived from multiple SCs ingestion, while
only one SC may be present in blood, confounding urine
metabolite results.
We developed a strategy for characterizing SC metabolism
and identifying suitable marker metabolites for new SC. The
goal was to rapidly publish results to enable clinical and
forensic toxicology laboratories to include target metabolites
into SC screening and confirmation methods, and to identify
Frontiers in Chemistry | www.frontiersin.org 12 March 2019 | Volume 7 | Article 109
Diao and Huestis Synthetic Cannabinoids Metabolism
optimal targets for reference manufacturers to synthesize as
analytical standards.
We recommend the following SC metabolism workflow:
(1) determine the SC’s half-life in HLM to properly design
human hepatocyte incubation; (2) incubate novel SC with
human hepatocytes; (3) identify the most characteristic and
abundant metabolites following hepatocytes incubation by HR-
MS; (4) if possible, obtain authentic positive urine specimens and
confirmmarker metabolites. To offset the cost of hepatocytes, we
recommend doing metabolism studies on 4–6 novel SCs at one
time with one vial of human hepatocytes. The excellent quality
data justifies human hepatocytes cost.
CONCLUSION
SC abuse is a significant public health problem, resulting in
many emergency department visits and fatalities. Despite
illicit drug scheduling by governments, novel SCs are
consistently introduced. To counter this growing challenge,
global collaboration is critical. Rapid information sharing
between government agencies and the scientific community is
essential. Excellent examples of relevant efforts are the European
Monitoring Centre for Drugs and Drug Addiction and the new
United Nations Office on Drugs and Crime Early Warning
Advisory Toxicology Portal. Rapid publication of marker
metabolites and availability of human urine specimens to verify
these markers for monitoring also are required.
Major hurdles are the cost of HR-MS for non-targeted urine
SC screening, and the time and skills required to determine
optimal SC marker metabolites from the highly complex HR-
MS data obtained after injection of the SC human hepatocyte
incubations (Pasin et al., 2017). Also, the size of the data
generated in non-targeted SC screening techniques is immense,
necessitating development of efficient and accurate data mining
techniques. It is clear that SC urinary metabolites do not
produce positive cannabinoid immunoassay tests; SC metabolite
screening and confirmation assays need to be constantly updated
to identify emerging SC intake. Collaboration between forensic
toxicology laboratories and legitimate suppliers of analytical
standardsmay result in better preparation and a timelier response
to future SC outbreaks. Increased recognition and reporting
by clinicians and public health personnel may aid federal and
state regulatory efforts in combating this ongoing SC epidemic.
It is important for clinicians and treatment personnel to stay
abreast of local trends and, when necessary, partner with
pharmacists, law enforcement, toxicologists, and mental health
providers to discuss strategies for addressing SC intake and their
resulting toxicities.
With global collaboration and communication, we can
educate the public and improve our response to the introduction
of novel SC. A positive trend is the recent reduction in new
SC introduced per year, perhaps a result of global collaboration,
especially the involvement of the Chinese government. However,
as governments tighten scheduling laws, more complicated or
uncommon principal cores or secondary substructures may
emerge onto the market. The need for forensic toxicologists to
identify the optimal target metabolites for these new SC and to
investigate new metabolic patterns is likely to continue into the
foreseeable future.
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